Trump Advisor Claims 'Someone' Blocking Cannabis Rescheduling Process

A Trump administration advisor claims unidentified parties are deliberately obstructing the federal cannabis rescheduling process, introducing fresh uncertainty into what has become the most closely watched regulatory development in the industry. The anonymous source's comments suggest internal political resistance may be complicating the Drug Enforcement Administration's review of marijuana's Schedule I classification, a process that began under the Biden administration.

The rescheduling delay carries substantial financial implications for cannabis operators who have been banking on federal tax relief through Section 280E elimination. Companies like Curaleaf Holdings (OTCQX: CURLF) and Green Thumb Industries (OTCQX: GTBIF) currently face effective tax rates exceeding 70% due to the federal prohibition on business expense deductions for Schedule I substances. A move to Schedule III would provide immediate margin expansion across the sector.

Multiple states continue advancing their own cannabis initiatives despite federal uncertainty. Massachusetts legislators are finalizing marijuana legislation headed to the governor's desk, while Maryland veterinarians prepare to vote on medical cannabis protocols. Louisiana hospitals are exploring medical marijuana programs, and Connecticut lawmakers are debating psychedelics policy frameworks. This state-level momentum creates a patchwork regulatory environment that complicates interstate commerce planning for multi-state operators.

The political dynamics surrounding rescheduling have shifted dramatically since the Trump administration's return to power. While Trump previously expressed support for state-level cannabis decisions, his administration's actual policy implementation remains unclear. The advisor's suggestion of internal obstruction indicates potential conflicts between different federal agencies or political factions over marijuana policy direction.

Investors are growing increasingly frustrated with the stop-and-start nature of federal cannabis reform. The sector has experienced multiple false starts on rescheduling expectations, creating volatility that has deterred institutional investment. Until clear federal guidance emerges, cannabis stocks will likely remain subject to policy-driven price swings rather than fundamental business performance, limiting the industry's access to traditional capital markets and banking services.